NSE ScannerRetail · Drugstore Chains · NSE: MEDPLUS · data 2026-10-31
MedPlus Health Services Ltd.
In plain words
Price: 43.3% below its 52-week high of ₹1,022.2.
Delivery: 54.3% of traded shares were kept for delivery over the last 10 sessions, against 59.2% over the last 60.
Latest results: a net profit of ₹56 cr for the quarter ended Sept 2026 (+1.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7,587 cr |
| Net profit (last 12 months) | ₹211 cr |
| Sales growth, 3 years (yearly) | 14.8% |
| Profit growth, 3 years (yearly) | 64.0% |
At a glance
Promoters 40.2% (-0.1 pts in a year), pledged 74.1%, institutions 44.5%.
P/E 33.0, P/B 3.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.8%, ROCE 10.9%, operating margin 4.2%: how much profit it earns on the money it uses.
Debt/equity 0.72, Profit growth 64.0% and sales growth 14.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 64.0% a year over 3 years.
- Thin operating margin (4.2%).
- Promoters have pledged 74.1% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
MEDPLUS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,037.11 crore, up 21.3% YoY and up 8.4% QoQ.
Net profit was ₹56.08 crore, up 1% YoY and up 69% QoQ.
Operating margin was 8.3% (8.9% a year ago).
EPS was ₹4.73, up 2.2% YoY and up 71.4% QoQ.
MEDPLUS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,037.11 करोड़; पिछले साल की तुलना में 21.3% की बढ़त, पिछली तिमाही की तुलना में 8.4% की बढ़त।
शुद्ध मुनाफ़ा: ₹56.08 करोड़; पिछले साल की तुलना में 1% की बढ़त, पिछली तिमाही की तुलना में 69% की बढ़त।
ऑपरेटिंग मार्जिन: 8.3% (एक साल पहले 8.9%)।
EPS: ₹4.73; पिछले साल की तुलना में 2.2% की बढ़त, पिछली तिमाही की तुलना में 71.4% की बढ़त।
MEDPLUSના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,037.11 કરોડ; ગયા વર્ષની સરખામણીએ 21.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 8.4% વધારો.
ચોખ્ખો નફો: ₹56.08 કરોડ; ગયા વર્ષની સરખામણીએ 1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 69% વધારો.
ઓપરેટિંગ માર્જિન: 8.3% (એક વર્ષ પહેલાં 8.9%).
EPS: ₹4.73; ગયા વર્ષની સરખામણીએ 2.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 71.4% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
31/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 66.6% over the last 20 sessions vs 61.8% in the 40 before (1.08x); shares delivered per day 0.94x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 3 schemes hold it, about ₹636 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 25 Aug 26Insider SAST disclosure: ICICI Prudential Mutual Fund +1 acquired 87,80,418 shares +2.3% next session
- 3 Aug 26Insider SAST disclosure: Catalyst Trusteeship Limited acquired 49,00,000 shares -3.0% next session
- 29 Jul 26Insider SAST disclosure: Catalyst Trusteeship Limited acting… acquired shares +2.0% next session
- 21 Jul 26Results Q1 FY27 results: profit −21.7% YoY -13.6% next session
- 20 May 26Results Q4 FY26 results: profit +24.6% YoY +2.1% next session
- 30 Jan 26Results Q3 FY26 results: profit +26.0% YoY +6.4% next session
- 31 Oct 25Results Q2 FY26 results: profit +43.3% YoY +8.2% next session
- 2 Aug 25Results Q1 FY26 results: profit +195.0% YoY +0.5% next session
- 27 May 25Results Q4 FY25 results: profit +53.7% YoY -1.2% next session
- 31 Jan 25Results Q3 FY25 results: profit +234.2% YoY +7.5% next session
- 13 Nov 24Results Q2 FY25 results: net profit ₹38.7 cr +4.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹2,037 cr | ₹56 cr | +1.0% | 8.3% | 4.73 |
| Jun 2026 | ₹1,880 cr | ₹33 cr | -21.7% | 7.1% | 2.76 |
| Mar 2026 | ₹1,864 cr | ₹64 cr | +24.6% | 9.1% | 5.33 |
| Dec 2025 | ₹1,806 cr | ₹58 cr | +26.0% | 8.8% | 4.82 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 40.19% | 40.19% | 40.22% | 40.29% |
| Foreign institutions (FII) | 12.58% | 14.38% | 15.53% | 16.83% |
| Domestic institutions (DII) | 31.89% | 29.95% | 27.82% | 26.57% |
| Mutual funds | 27.39% | 24.51% | 22.60% | 21.48% |
| Retail investors | 8.96% | 9.02% | 9.31% | 9.13% |
| Number of shareholders | 77,714 | 76,005 | 77,278 | 79,157 |
Common questions
What was MedPlus Health Services Ltd.'s latest quarterly profit?
MedPlus Health Services Ltd. reported a net profit of ₹56 cr for the quarter ended Sept 2026 (+1.0% on the same quarter a year earlier), on revenue of ₹2,037 cr.
How much do promoters hold in MedPlus Health Services Ltd.?
Promoters held 40.19% of MedPlus Health Services Ltd. at the end of Sept 2026, with 74.09% of promoter shares pledged.
Is MedPlus Health Services Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.72.
What is MedPlus Health Services Ltd.'s P/E ratio?
About 33, based on the last 12 months' earnings and a price of ₹579.9 (data 2026-10-31).
What is the 52-week high and low of MedPlus Health Services Ltd.?
The 52-week high is ₹1,022.2 and the 52-week low is ₹565.6.
Mutual funds holding MedPlus Health Services Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹636 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI ELSS Tax Saver Fund | SBI Mutual Fund | 0.89% | ₹267 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.53% | ₹232 cr |
| Nippon India Focused Fund | Nippon India Mutual Fund | 1.70% | ₹137 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| MedPlus Health Services Ltd. | ₹579.9 | ₹6,966 cr | 33 | 3.4 | 11.8% | 10.9% | 0.72 | -22.8% |
| Brainbees Solutions Limited | ₹157.76 | ₹8,244 cr | — | — | -2.9% | -2.6% | 0.33 | -55.9% |
| Aditya Vision Ltd. | ₹549.05 | ₹7,111 cr | 49.2 | 9.2 | 18.4% | 22.9% | 0.83 | -4.5% |
| Ethos Ltd. | ₹2,501.7 | ₹6,698 cr | 64.3 | — | 7.7% | 8.3% | 0.22 | -13.5% |
| V-Mart Retail Ltd | ₹739.5 | ₹5,882 cr | 42.9 | 5.9 | 14.1% | 13.8% | 1.3 | -10.4% |
| Electronics Mart India Limited | ₹151.74 | ₹5,835 cr | 28.3 | — | 6.8% | 10.4% | 1.23 | +1.0% |
Compare MEDPLUS with FIRSTCRY in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDPLUS in NSE Scanner →